Lehigh Valley Health Network

Research Scholars Poster Presentation

The Impact of New Commercial Tests Evaluating Cell-free Fetal DNA in Maternal Circulation for Aneuploidy Detection in High-risk Patients

Camille Campion Bates College

Meredith Rochon MD Lehigh Valley Health Network, Meredith_L.Rochon@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/research-scholars-posters Let us know how access to this document benefits you

Published In/Presented At

Campion, C., Rochon, M., (2014, July, 25) *The impact of new commercial tests evaluating cell-free fetal DNA in maternal circulation for aneuploidy detection in high-risk patients.* Poster presented at LVHN Research Scholar Program Poster Session, Lehigh Valley Health Network, Allentown, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

The impact of new commercial tests evaluating cell-free fetal DNA in maternal circulation for an euploidy detection in high-risk patients

Background

- Fetal aneuploidy is an abnormal number of chromosomes in a fetus's DNA caused by missing or extra chromosomes that originate during cell division.
- An abnormal number of chromosomes can result in genetic disorders and birth defects.
- Three most common types of aneuploidy
 - Trisomy 21 (Down syndrome)
 - Trisomy 18 (Edwards syndrome)
 - Trisomy 13 (Patau syndrome)
- Screening for fetal aneuploidy is important in both low-risk and high-risk pregnancy patients.
- Invasive tests, amniocentesis and chronic villus sampling (CVS), provide the most accurate information, but are associated with a small risk of miscarriage.
- Non-invasive tests, performed by obtaining maternal blood, are not associated with a risk of miscarriage but they do not have high accuracy with detection rates of 70-92% for an euploidy (1).
- Cell-free fetal DNA (cffDNA), introduced in the fall of 2011, is a new form of non-invasive aneuploidy tests for the diagnosis of fetal trisomy 13, 18, and 21
 - Sensitivities and specificities for the three different aneuploidies approach 100% (2).
- The purpose of this study is to assess how the introduction of cffDNA tests on a population of high-risk patients from Maternal Fetal Medicine of LVHN has affected the use of invasive procedures in the practice over a period of time.


Methods

- Retrospective cohort study
- Inclusion criteria:
 - Women determined to be at high-risk for an uploidy seen in Maternal Fetal Medicine at LVHN from 1/01/2012 to 12/31/13, who underwent cffDNA testing
- Indicatiors of "high-risk":
 - Advanced maternal age (AMA-maternal age \geq 35)
 - Abnormal maternal serum screen
 - Abnormal ultrasound findings
 - Family/personal history of aneuploidy
- Exclusion criteria:
 - Women at low-risk for fetal aneuploidy
- Tests performed during this study period:
 - MaterniT21 Plus (Sequenom CMM)
 - Verifi Prenatal Test (Verinata)
 - Harmony Prenatal Test (Integrated Genetics)
- Results were reported as:
 - Mat21: "positive", "negative", or "non-reportable"
 - Non-reportable results were due to insufficient fetal DNA from maternal serum and women were offered a redraw on an invasive test
 - Verifi: "aneuploidy detected", "aneuploidy not detected", or "unclassifiable" • Unclassifiable results are those found to be in the "gray zone" or
 - overlap between what is considered positive and negative for a specific aneuploidy
 - Women with this result were not offered a redraw per lab protocol but were offered invasive testing
 - Harmony: "high-risk" or "low-risk"
- Neonatal records and maternal postpartum visit records were reviewed whenever possible to confirm neonatal outcome and identify false positive and/or false negative results
- Descriptive statistics were generated using Excel 2010
- Utilization of cffDNA as compared to invasive testing over time was determined

Campion, C; Rochon, M.

Lehigh Valley Health Network, Allentown, Pennsylvania

	R	esults		
	Figure 1: Primary indica	tion for cffDNA s	 Advanced mate Abnormal ultras Abnormal serur Personal/family 	sound n screen
able 1. Results of ce	II-free fetal DNA testing	3 Table 2. Pre	gnancy continuation a	after positive results
Vegative	922/956 (96.4%)	Continuatio	on of pregnancy	19/28 (67.9%)
ositive	28/956 (2.9%)	Live birt	h	16/19
on-reportable	5/956 (0.5%)	Miscarri	age	3/19
Jnclassifiable	1/956 (0.1%)	Terminatio	n	9/29 (32.1%)
able 3. Test perform	ance for detection of T	risomy 21*		
	Sensitivity	Specificity	Positive Predictive Value	Negative Predictive Value
Frisomy 21	94.7%	100%	100%	99.9%
	DNA test utilization over		ars offered as compare	ed to the utilization of
160 140 120				 →Invasive Procedures
100 80				cff-DNA



A PASSION FOR BETTER MEDICINE.

Results

ents underwent cell-free fetal DNA testing during the eriod. 2 cancelled the test prior to getting results for a nort of 956 patients

ed maternal age was the most common indication for Figure 1)

nts had non-reportable results on initial testing. Of the were retested, 4 results remained unreportable and returned negative.

vere 28 (2.9%) positive and 1 (0.1%) unclassifiable Table 1). The majority of the positive results were

patients opted to confirm abnormal results with testing. All women with confirmed abnormal results sive testing terminated the pregnancy.

vomen with positive results, 68% continued the cy (Table 2).

formance was high (Table 3).

e fetal DNA test utilization increased significantly over gure 2) and was associated with a concomitant se in the number of invasive tests being performed.

Conclusion

e fetal DNA (cffDNA) is a new prenatal bidy screening test being used with increasing icy in high risk obstetrical patients

ation of cffDNA is increasing, performance of e (diagnostic) procedures is decreasing

h detection rates are much better than older bidy screening tests, cffDNA should be

ered a screen, not a diagnostic test, as it does

are false positive and false negative results. It is re important to confirm positive cffDNA results invasive test.

studies should look at test performance in lowoulations.

ES

sive Prenatal Diagnosis of Fetal Aneuploidy Using Cell-Free Fetal Acids in Maternal Blood: Clinical Policy (Effective 05/01/2014) ni DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, et al. (2012) -wide fetal aneuploidy detection by maternal plasma DNA sequencing. ynecol 119: 890–9012014 Lehigh Valley Health Network

